LLY.BA Eli Lilly and Company
Company Analysis
Latest News
Lilly's Oncology Bet Gets an FDA Fast Lane, but Can a Niche Cancer Drug Move the Needle for an $80 Billion Revenue Machine?
Shares of Eli Lilly surged 6.2% to $33,380 on August 7, rebounding sharply from a multi-day slide, after the FDA granted Breakthrough Therapy designation to...
Lilly's Oncology Bet Gets an FDA Fast Lane, but Can a Niche Cancer Drug Move the Needle for an $80 Billion Revenue Machine?
Shares of Eli Lilly surged 6.2% to $33,380 on August 7, rebounding sharply from a multi-day slide, after the FDA granted Breakthrough Therapy designation to...
Lilly's Oncology Bet Gets an FDA Fast Lane, but Can a Niche Cancer Drug Move the Needle for an $80 Billion Revenue Machine?
Shares of Eli Lilly surged 6.2% to $33,380 on August 7, rebounding sharply from a multi-day slide, after the FDA granted Breakthrough Therapy designation to...
🟢 Eli Lilly is trading 4.77% up today after Q2 earnings beat and raised 2026 revenue guidance
Eli Lilly is trading 4.77% up now at ARS 32940 after strong second-quarter results and higher full-year revenue guidance. • Q2 revenue reached $23.0 billion,...
🟢 Eli Lilly is trading 6.2% up today after Q2 earnings beat and FDA breakthrough designation
Eli Lilly is trading 6.2% up today at $33,380 following stronger-than-expected Q2 earnings, positive oncology news, and a broader market rally. • The company...
Lilly secures FDA breakthrough status for pancreatic cancer drug, olomorasib
Eli Lilly received FDA Breakthrough Therapy designation for its drug olomorasib. The treatment targets adult patients with KRAS G12C-mutant advanced...
Eli Lilly's Zepbound joins Indiana Medicaid, cutting state costs to $85
Eli Lilly’s GLP-1 weight-loss medications, Zepbound and Foundayo, are now accessible to eligible Indiana Medicaid beneficiaries. The state secured these drugs...
Eli Lilly invests $750M to expand US production, meeting record obesity demand
Eli Lilly and Company partnered with Resilience to invest $750 million in U.S. manufacturing capacity. This capital will expand domestic production for the...
🔴 Eli Lilly is trading 5.4% down today on healthcare sector margin concerns
Eli Lilly is trading 5.4% down at ARS 32,360.00 today, moving largely in step with a broader healthcare sector selloff. • The decline is primarily driven by...
🔴 Eli Lilly is trading 4.3% down today on healthcare sector margin concerns
Eli Lilly is trading 4.3% down at ARS 32,740.00 as managed care margin concerns weigh on the broader healthcare sector. • The move appears driven by...
Eli Lilly advances retatrutide, hitting 22.6% weight loss in Phase 3 trials
Eli Lilly and Company reported positive topline results from the TRIUMPH-2 and TRIUMPH-3 Phase 3 trials for retatrutide. The investigational drug is a...
Novo Nordisk sues Eli Lilly, alleging deceptive Zepbound and Mounjaro ads
Novo Nordisk filed a lawsuit Tuesday in U.S. federal court against Eli Lilly. The suit accuses Lilly of false advertising and unfair competition regarding its...
Eli Lilly buys AtaiBeckley for $2.8B, targeting psychedelic depression treatments
Eli Lilly has agreed to acquire clinical-stage biotech AtaiBeckley for an upfront cash payment of $2.8 billion. The deal prices AtaiBeckley at $6.75 per share....
Eli Lilly Target Raised to $1,385, Anticipating Earnings Beat
Bernstein SocGen Group increased its price target for Eli Lilly to $1,385 from $1,300. The firm maintains an Outperform rating on the pharmaceutical...
🔴 Eli Lilly is trading 4.1% down today as HCA Healthcare profit cut pressures sector
Eli Lilly is trading 4.1% down today at $31,920.00 as the healthcare sector slides following a full-year profit outlook cut from HCA Healthcare. • The...
Eli Lilly Showcases Kisunla Data, Highlighting New Alzheimer's Blood Test Results
Eli Lilly began participating in the Alzheimer's Association International Conference (AAIC) in London today. The event runs from July 12-15. The company...
Eli Lilly Price Target Raised to $1,400 by JPMorgan on Strong GLP-1 Momentum
JPMorgan Chase & Co. increased its price target for Eli Lilly and Company to $1,400 from $1,300, maintaining an "overweight" rating on the stock. The new...
Eli Lilly expands Asia distribution, Cantor Fitzgerald hikes price target
Eli Lilly and Company partnered with DKSH Business Unit Healthcare to distribute pharmaceutical products in Hong Kong and Macau. This agreement expands on...
🟢 LLY.BA is trading 2.1% up today on the launch of Medicare GLP-1 Bridge program
Eli Lilly's stock is up 2.1% today at $34,600 following the launch of its Medicare GLP-1 Bridge program. • The program, effective July 1, 2026, significantly...
🔴 LLY.BA is trading 2.3% down today on profit-taking after recent gains
LLY.BA is trading 2.3% down at $33,220.00 as the stock pulls back following a period of strong momentum and no new company-specific news. • The move is...